- In July 2021, Denali Therapeutics Inc. reported promising results from their clinical study evaluating ETV: IDS, an investigational brain-penetrant enzyme replacement therapy for treating the peripheral manifestations of Hunter Syndrome. These results are set to be presented at the 16th International Symposium on MPS and Related Diseases
- In December 2023, Orchard Therapeutics has been granted priority review by the US Food and Drug Administration (FDA) for its gene therapy OTL-203 targeting Hurler Syndrome. This designation provides several expedited drug development benefits, designed to accelerate the progress of treatments for serious conditions. Orchard is advancing a hematopoietic stem cell (HSC) gene therapy to address Hurler Syndrome, a rare lysosomal storage disorder also known as mucopolysaccharidosis type I
Frequently Asked Questions
The market is segmented based on Segmentation, By Drugs (Elosulfase Alfa, Laronidase and Others), Treatment (Medication, Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant (HSCT) and Surgery), Disease Type ( Mucopolysaccharidoses I, Mucopolysaccharidoses II, Mucopolysaccharidoses III, (Mucopolysaccharidoses IIIA, Mucopolysaccharidoses IIIB, Mucopolysaccharidoses IIIC, Mucopolysaccharidoses IIID), Mucopolysaccharidoses IV (Mucopolysaccharidoses IVA, Mucopolysaccharidoses IVB), Mucopolysaccharidoses VI, Mucopolysaccharidoses VII and Mucopolysaccharidoses IX), Route of Administration (Oral and Parenteral), Distribution Channel (Direct, Online Pharmacy, Retailers and Others) and End Users (Hospitals, Homecare, Specialty Clinics and Others) – Industry Trends and Forecast to 2032.
.
The Global Hurler Syndrome Treatment Market size was valued at USD 594.86 USD Million in 2024.
The Global Hurler Syndrome Treatment Market is projected to grow at a CAGR of 8.3% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
